Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-445/tezacaftor/ivacaftor in cystic fibrosis subjects homozygous for F508del
2019-001735-31Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing elexacaftor + tezacaftor + ivacaftor with tezacaftor + ivacaftor control (2 arms). Primary endpoint: Absolute change in CF Questionnaire-Revised respiratory domain score from baseline through Week 24. Started Jun 2019; status: completed.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2019-001735-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001735-31.